Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Venlafaxine besylate monohydrate.

ABSTRACT: The title compound {systematic name: [2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl]dimethylazanium benzene-sulfonate monohydrate}, C17H28NO2 (+)·C6H5O3S(-)·H2O, is a besylate salt hydrate of the anti-depressant drug venlafaxine. In the crystal, besylate anions and water mol-ecules self-assemble, forming hydrogen-bonded dimers linked around inversion centers, with graph set R 4 (4)(6). The crystal packing features a chain of alternate dimers and venlafaxine cations in the b-axis direction with the components linked by O-H?O hydrogen bonds and C-H?O and C-H?? inter-actions. This is the first example of a venlafaxine cation with a closed conformation, as it features an intra-molecular N-H?O inter-action involving the protonated N atom.

SUBMITTER: Corvalan CH

PROVIDER: S-EPMC3885021 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Venlafaxine besylate monohydrate.

Corvalan Carolina H CH Vega Daniel R DR

Acta crystallographica. Section E, Structure reports online 20131106 Pt 12

The title compound {systematic name: [2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl]dimethylazanium benzene-sulfonate monohydrate}, C17H28NO2 (+)·C6H5O3S(-)·H2O, is a besylate salt hydrate of the anti-depressant drug venlafaxine. In the crystal, besylate anions and water mol-ecules self-assemble, forming hydrogen-bonded dimers linked around inversion centers, with graph set R 4 (4)(6). The crystal packing features a chain of alternate dimers and venlafaxine cations in the b-axis direction wit ...[more]

PMID: 24454196

Similar Datasets

Pharmacokinetics of amlodipine besylate at delivery and during lactation.

Project description:BACKGROUND:Amlodipine is rarely used in the treatment of pregnant hypertensive women due to limited pharmacokinetic data during pregnancy and the postpartum period. OBJECTIVE:To evaluate the pharmacokinetics of amlodipine besylate in the peri-partum period including quantities of placental passage, breast milk excretion and infant exposure. STUDY DESIGN:This was a prospective study of pregnant women who were prescribed 5 mg of amlodipine daily for treatment of chronic hypertension and delivered at term. Cord and maternal blood samples were collected at delivery. On postpartum day 2, six paired maternal plasma and breast milk samples were obtained at 4, 6, 8, 12, 15 and 24 h following amlodipine dosing. Infant plasma samples were collected 24-48 h after delivery. All samples were analyzed for amlodipine concentration. A one compartment, first-order model was used to calculate pharmacokinetic estimates for maternal plasma. RESULTS:Of the 16 patients enrolled in the study, 11 had cord blood and maternal serum collected at delivery, of which only 6 produced sufficient breast milk for sampling. Amlodipine was detected in infant cord blood plasma with a mean concentration of 0.49 ± 0.29 ng/mL compared to mean maternal serum level of 1.27 ± 0.84 ng/mL. Amlodipine concentrations in both in breast milk and infant plasma were undetectable at the lower limit of assay detection (<0.1 ng/mL). In the immediate postpartum period, the amlodipine elimination half-life was 13.7 ± 4.9 h, the area under the curve was 53.4 ± 19.8 ng*h/mL and the peak concentration was 2.0 ± 1.0 ng/mL. CONCLUSIONS:Amlodipine does cross the placenta in measurable quantities, but is not detected in breast milk or infant plasma at 24-48 h of life indicating that it is likely safe to use during the peripartum period.

| S-EPMC5846630 | biostudies-literature

Bone Turnover with Venlafaxine Treatment in Older Adults with Depression.

Project description:Epidemiologic data suggest older adults receiving serotonergic antidepressants may have accelerated bone loss. We examined bone turnover marker changes and patient-level variables associated with these changes in older adults receiving protocolized antidepressant treatment.Open-label, protocolized treatment study.Medical centers in Pittsburgh, St Louis, and Toronto.Older adults with major depression (N = 168).Serum levels of the bone resorption marker C-terminal cross-linking telopeptide of type 1 collagen (CTX) and the bone formation marker procollagen type 1 N propeptide (P1NP) were assayed before and after 12 weeks of treatment with venlafaxine. Whether CTX and P1NP changes were associated with depression remission and duration of depression and genetic polymorphisms in the serotonin transporter (5HTTLPR) and 1B receptor (HTR1B) were also examined.CTX increased and P1NP decreased during venlafaxine treatment, a profile consistent with accelerated bone loss. Two individual-level clinical variables were correlated with bone turnover; participants whose depression did not go into remission had higher CTX levels, and those with chronic depression had lower P1NP levels. HTR1B genotype predicted P1NP change, whereas 5HTTLPR genotype was unrelated to either biomarker.Bone turnover markers change with antidepressant treatment in a pattern that suggests accelerated bone loss, although the clinical significance of these changes is unclear. These data are preliminary and argue for a larger, controlled study to confirm whether antidepressants are harmful to bone metabolism and whether certain individuals might be at increased risk.

| S-EPMC5626017 | biostudies-literature

Effects of norfluoxetine and venlafaxine in zebrafish larvae: Molecular data.

Project description:The data presented herein relates to the article entitled "Norfluoxetine and venlafaxine in zebrafish larvae: single and combined toxicity of two pharmaceutical products relevant for risk assessment" [1]. Recent studies have shown the occurrence of active metabolites of human and veterinary pharmaceuticals in surface and wastewaters. Besides their biological activity, some are predicted to interact with the same molecular targets of their parental compounds, thus showing the potential to elicit detrimental effects on animals. Despite this, limited investigation on their effects on aquatic animals has been done. Genomic material resulting from zebrafish (Danio rerio) larvae exposed to the psychoactive compounds norfluoxetine (main fluoxetine metabolite), venlafaxine, or their mixture was collected for gene expression analysis of a determined pool of genes potentially involved in their mode-of-action and metabolism. Molecular parameters are a cost-effective and reliable way to understand modes-of-action and the potential risk of micropollutants, such as pharmaceutical products, in non-target organisms. Moreover, gene expression patterns can provide crucial complementary information to improve risk assessment, and monitoring of affected systems. The data reported in this article was used to depict the effects of single or combined exposure to norfluoxetine and venlafaxine and identify biomarkers of exposure to these compounds of interest to diagnose exposure and routine monitoring.

| S-EPMC7689041 | biostudies-literature

Effects of MDMA and Venlafaxine treatment in Dark Agouti rats

Project description:The aim of this study was to examine the hippocampus, frontal cortex and dorsal raphe of Dark Agouti rats with gene expression arrays (Illumina RatRef bead arrays) looking for possible mechanisms and new candidates contributing to the effects of a single dose of MDMA (15 mg/kg) 3 weeks earlier or venlafaxine (40 mg/kg) administration for 3 weeks continously. We also examined the possible interaction between the single dose MDMA treatment and the continous venlafaxine treatment described above.

2013-06-01 | GSE47541 | GEO

Sodium 2-mercaptoethanesulfonate monohydrate (coenzyme M sodium salt monohydrate).

Project description:The 2-thio-ethanesulfonate anion is the smallest known coenzyme in nature (HS-CoM) and plays a key role in methano-genesis by anaerobic archaea, as well as in the oxidation of alkenes by Gram-negative and Gram-positive eubacteria. The title compound, Na(+)·C(2)H(5)O(3)S(2) (-)·H(2)O, is the Na(+) salt of HS-CoM crystallized as the monohydrate. Six O atoms form a distorted octa-hedral coordination geometry around the Na atom, at distances in the range 2.312 (4)-2.517 (3) Å. Two O atoms of the sulfonate group, one O atom of each of three other symmetry-related sulfonate groups plus the water O atom form the coordination environment of the Na(+) ion. This arrangement forms Na-O-Na layers in the crystal structure, parallel to (100).

| S-EPMC2959637 | biostudies-literature

Venlafaxine Caffeic Acid Salt: Synthesis, Structural Characterization, and Hypoglycemic Effect Analysis.

Project description:Depression is a recurrent and chronic mental disorder requiring long-term treatment. Major depressive disorder is present in 15-20% of patients with type 1 or type 2 diabetes. Large-scale evidence revealed that depression and depressive symptoms are independent risk factors for the development of type 2 diabetes, and they may contribute to hyperglycemia and even accelerate the premature onset of diabetes complications. Venlafaxine is a clinical first-line antidepressant used for more than 30 years. Recently, clinical reports showed that venlafaxine overdose might cause hypoglycemia. Venlafaxine is insoluble and salt formation technology is the most appropriate method to improve the physicochemical properties and the pharmacokinetic profile of the drug. In the present work, the use of the solvent evaporation method, slurry, and the liquid-assisted grinding method resulted in the crystalline salt venlafaxine-caffeic acid (1:1). The compounds were characterized using a series of solid-state techniques, viz., powder X-ray diffraction, differential scanning calorimetry, thermogravimetric analysis, Fourier transform infrared spectroscopy, and solid-state nuclear magnetic resonance, and the crystal structure was determined by single-crystal X-ray diffraction. Besides, a comparative study of solubility, dissolution, and hypoglycemic activity of the parent drug and the new salt has been carried out. The tested venlafaxine-caffeic acid salt showed about 16-fold higher solubility than the pure drug. Moreover, the glucose consumption assay results showed that the novel salt possesses potent hypoglycemic activity in vitro, suggesting that it is a promising candidate effective for major depressive disorder patients with type 2 diabetes.

| S-EPMC8173613 | biostudies-literature

Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults.

Project description:BackgroundVenlafaxine, a serotonin-norepinephrine reuptake inhibitor, is often used as first- or second-line therapy for depression in older adults. It can be associated with adverse blood pressure (BP) effects.MethodsAdults ⩾60 years of age in a current major depressive episode were treated in a protocolized manner with venlafaxine XR; 429 participants were treated for 8-16 weeks with a daily dose up to 300 mg to achieve remission from depression. Cardiac measures included sitting and standing BP and heart rate.ResultsOf participants who were normotensive at baseline, 6.5% were found to have elevated BP during the study (1.9% <225 mg/day; 9.8% ⩾225 mg/day). There was no significant change in mean BP in the overall sample, or in the subgroup treated with doses ⩾225 mg/day. Additionally, 20.1% of the participants who did not have orthostatic hypotension at baseline were found to have orthostatic hypotension (16.8% <225 mg/day; 22.4% ⩾225 mg/day). Participants with new-onset orthostatic hypotension were significantly more likely to fall than the other participants.ConclusionA large proportion of older adults treated with venlafaxine experience orthostatic hypotension, putting them at risk for falls. A smaller proportion experience elevated BP. Older patients prescribed venlafaxine, particularly at high doses, should be advised and counseled about these adverse effects.

| S-EPMC8200287 | biostudies-literature

Bosentan monohydrate.

Project description:In the title compound, C27H29N5O6S·H2O {systematic name: 4-tert-butyl-N-[6-(2-hy-droxy-eth-oxy)-5-(2-meth-oxy-phen-oxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide monohydrate], the dihedral angle between the mean planes of the pyrimidine rings is 27.0?(1)°. The dihedral angle between the mean planes of the benzene rings is 47.7?(8)°, forming a U-shaped channel around the chain of twisted pyrimidine rings. The crystal packing is stabilized by O-H?O, O-H?N and N-H?O hydrogen bonds with a single water mol-ecule, and weak O-H?N inter-molecular inter-actions between the hy-droxy group and one of the pyrimidine rings producing an two-dimensional supra-molecular array in the bc plane. The title compound studied was a merohedral twin with the major component being approximately 57%.

| S-EPMC3588285 | biostudies-literature

Isovaline monohydrate.

Project description:The title compound, C5H11NO2·H2O, is an isomer of the ?-amino acid valine that crystallizes from water in its zwitterion form as a monohydrate. It is not one of the 20 proteinogenic amino acids that are used in living systems and differs from the natural amino acids in that it has no ?-H atom. The compound exhibits hydrogen bonding between the water mol-ecule and the carboxyl-ate O atoms and an amine H atom. In addition, there are inter-molecular hydrogen-bonding inter-actions between the carboxyl-ate O atoms and amine H atoms. In the crystal, these extensive N-H?O and O-H?O hydrogen bonds lead to the formation of a three-dimensional network.

| S-EPMC3885077 | biostudies-literature

Raltegravir monohydrate.

Project description:THE HYDRATED TITLE COMPOUND [SYSTEMATIC NAME: N-(4-fluoro-benz-yl)-5-hy-droxy-1-methyl-2-{1-methyl-1-[(5-methyl-1,3,4-oxa-diazol-2-ylcarbon-yl)amino]-eth-yl}-6-oxo-1,6-di-hydro-pyrimidine-4-carb-oxamide monohydrate], C20H21FN6O5·H2O, is recognised as the first HIV integrase inhibitor. In the mol-ecule, the dihedral angles between the mean planes of the pyrimidine ring and the phenyl and oxa-diazole rings are 72.0 (1) and 61.8 (3)°, respectively. The mean plane of the oxa-diazole ring is twisted by 15.6 (3)° from that of the benzene ring, while the mean plane of amide group bound to the oxadiaole ring is twisted by 18.8 (3)° from its mean plane. Intra-molecular O-H⋯O and C-H⋯N hydrogen bonds are observed in the mol-ecule. The crystal packing features O-H⋯O hydrogen bonds, which include bifurcated O-H⋯(O,O) hydrogen bonds from one H atom of the water mol-ecule. In addition, N-H⋯O hydrogen bonds are observed involving the two amide groups. These inter-actions link the mol-ecules into chains along [010].

| S-EPMC3885024 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data